107 related articles for article (PubMed ID: 8299855)
1. Effect of prostaglandin E1 on the renin-aldosterone system in patients with diabetic nephropathy.
Okada S; Ichiki K; Tanokuchi S; Ishii K; Hamada H; Ota Z
J Int Med Res; 1993; 21(3):126-32. PubMed ID: 8299855
[TBL] [Abstract][Full Text] [Related]
2. Influence of prostaglandin E1 on heavy proteinuria in slightly azotaemic diabetics.
Okada S; Sato K; Higuchi T; Ichiki K; Tanokuchi S; Ishii K; Hamada H; Ota Z
J Int Med Res; 1991; 19(2):171-3. PubMed ID: 1864454
[TBL] [Abstract][Full Text] [Related]
3. Influence of prostaglandin E1 on slight proteinuria in non-azotaemic diabetics.
Okada S; Sato K; Higuchi T; Ichiki K; Tanokuchi S; Ishii K; Hamada H; Ota Z
J Int Med Res; 1992 Feb; 20(1):94-7. PubMed ID: 1568524
[TBL] [Abstract][Full Text] [Related]
4. Proteinuria-lowering effect of heparin therapy in diabetic nephropathy without affecting the renin-angiotensin-aldosterone system.
Benck U; Haeckel S; Clorius JH; van der Woude FJ
Clin J Am Soc Nephrol; 2007 Jan; 2(1):58-67. PubMed ID: 17699388
[TBL] [Abstract][Full Text] [Related]
5. Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy.
Eyileten T; Sonmez A; Saglam M; Cakir E; Caglar K; Oguz Y; Vural A; Yenicesu M; Yilmaz MI
Nephrology (Carlton); 2010 Mar; 15(2):225-9. PubMed ID: 20470283
[TBL] [Abstract][Full Text] [Related]
6. Decreased creatinine clearance which may be observed during prostaglandin E1 therapy: is it reversible with discontinuation of therapy?
Okada S; Miyai Y; Sato K; Higuchi T; Ichiki K; Tanokuchi S; Ishii K; Hamada H; Ota Z
J Int Med Res; 1991; 19(6):493-6. PubMed ID: 1773910
[TBL] [Abstract][Full Text] [Related]
7. Renal effects of prostaglandin E1 in type 2 (non-insulin-dependent) diabetic patients with subclinical nephropathy.
Ninomiya Y; Arakawa M
Diabetes Res; 1989 Mar; 10(3):129-34. PubMed ID: 2680226
[TBL] [Abstract][Full Text] [Related]
8. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
[TBL] [Abstract][Full Text] [Related]
9. Effect of prostaglandin E1 on renal haemodynamics in a patient with diabetic nephropathy.
Okada S; Ogino Y; Ichiki K; Tanokuchi S; Ishii K; Hamada H; Ota Z; Hiraki Y
J Int Med Res; 1991; 19(6):497-500. PubMed ID: 1773911
[TBL] [Abstract][Full Text] [Related]
10. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
Krairittichai U; Chaisuvannarat V
J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
[TBL] [Abstract][Full Text] [Related]
11. Increased renin release by exogenous prostaglandin E1 in liver cirrhosis with and without ascites.
Uemasu J; Kawasaki H; Hirayama C
Horm Metab Res; 1988 May; 20(5):302-5. PubMed ID: 3042580
[TBL] [Abstract][Full Text] [Related]
12. Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan.
Guo LL; Pan Y; Jin HM
Nephrol Dial Transplant; 2009 Jun; 24(6):1876-83. PubMed ID: 19164322
[TBL] [Abstract][Full Text] [Related]
13. Effects on the renin-angiotensin system of the administration of prostaglandin E1 and E2 in second trimester human pregnancy.
Broughton Pipkin F; Hunter JC; O'Brien PM; Sant-Cassia LJ; Turner SR
Clin Exp Hypertens B; 1983; 2(2):233-45. PubMed ID: 6347443
[TBL] [Abstract][Full Text] [Related]
14. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.
Kang YS; Ko GJ; Lee MH; Song HK; Han SY; Han KH; Kim HK; Han JY; Cha DR
Nephrol Dial Transplant; 2009 Jan; 24(1):73-84. PubMed ID: 18682491
[TBL] [Abstract][Full Text] [Related]
15. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
[TBL] [Abstract][Full Text] [Related]
16. [Prostaglandin E1 suppresses hypersecretion of antidiuretic hormone induced by surgical stress].
Enzan K; Sato W; Nagata H; Matsuura S; Suzuki M
Masui; 1994 Feb; 43(2):233-7. PubMed ID: 8164328
[TBL] [Abstract][Full Text] [Related]
17. [Effects of 6-oxo-PGE1 on the renin-angiotensin-aldosterone system, blood pressure and platelet aggregability in man].
Morise T; Miyamori I; Ikeda M; Takeda Y; Koshida H; Yasuhara S; Takeda R
Nihon Naibunpi Gakkai Zasshi; 1983 Aug; 59(8):1138-44. PubMed ID: 6686560
[TBL] [Abstract][Full Text] [Related]
18. Possible participation of a prostaglandin E1 analogue in the aggravation of diabetic nephropathy.
Aoki Y; Yanagisawa Y; Oguchi H; Yazaki K; Furuta S
Diabetes Res Clin Pract; 1992 Jun; 16(3):233-8. PubMed ID: 1425144
[TBL] [Abstract][Full Text] [Related]
19. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
[TBL] [Abstract][Full Text] [Related]
20. Does a dose of 40 micrograms/day prostaglandin E1 reduce creatinine clearance in a patient with diabetic nephropathy of the nephrotic type?
Okada S; Hamada H; Ichiki K; Tanokuchi S; Ishii K; Ota Z; Hiraki Y
J Int Med Res; 1992 Apr; 20(2):190-6. PubMed ID: 1521675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
